Your browser doesn't support javascript.
loading
Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment.
Prezioso, Carla; Ciotti, Marco; Brazzini, Gabriele; Piacentini, Francesca; Passerini, Sara; Grimaldi, Alfonso; Landi, Doriana; Nicoletti, Carolina Gabri; Zingaropoli, Maria Antonella; Iannetta, Marco; Altieri, Marta; Conte, Antonella; Limongi, Dolores; Marfia, Girolama Alessandra; Ciardi, Maria Rosa; Mastroianni, Claudio Maria; Palamara, Anna Teresa; Moens, Ugo; Pietropaolo, Valeria.
Afiliación
  • Prezioso C; IRCSS San Raffaele Roma, Microbiology of Chronic Neuro-Degenerative Pathologies, 00163 Rome, Italy.
  • Ciotti M; Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, 00185 Rome, Italy.
  • Brazzini G; Laboratory of Virology, Polyclinic Tor Vergata Foundation, 00133 Rome, Italy.
  • Piacentini F; Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, 00185 Rome, Italy.
  • Passerini S; Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, 00185 Rome, Italy.
  • Grimaldi A; Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, 00185 Rome, Italy.
  • Landi D; Multiple Sclerosis Clinical and Research Unit, Fondazione Policlinico di Tor Vergata, 00133 Rome, Italy.
  • Nicoletti CG; Multiple Sclerosis Clinical and Research Unit, Fondazione Policlinico di Tor Vergata, 00133 Rome, Italy.
  • Zingaropoli MA; Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy.
  • Iannetta M; Multiple Sclerosis Clinical and Research Unit, Fondazione Policlinico di Tor Vergata, 00133 Rome, Italy.
  • Altieri M; Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy.
  • Conte A; Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, 00185 Rome, Italy.
  • Limongi D; Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy.
  • Marfia GA; Department of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy.
  • Ciardi MR; Department of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy.
  • Mastroianni CM; IRCCS Neuromed, 86077 Pozzilli, IS, Italy.
  • Palamara AT; IRCCS San Raffaele Roma, Telematic University, 00163 Rome, Italy.
  • Moens U; Multiple Sclerosis Clinical and Research Unit, Fondazione Policlinico di Tor Vergata, 00133 Rome, Italy.
  • Pietropaolo V; Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy.
J Clin Med ; 11(2)2022 Jan 11.
Article en En | MEDLINE | ID: mdl-35054041
ABSTRACT
Markers of JC polyomavirus (JCPyV) activity can be used to evaluate the risk of progressive multifocal leukoencephalopathy (PML) in treated multiple sclerosis (MS) patients. The presence of JCPyV DNA and microRNA (miR-J1-5p), the anti-JCV index and the sequence of the non-coding control region (NCCR) in urine and plasma were determined in 42 MS subjects before treatment (T0), 6 months (T6) and 12 months (T12) after natalizumab, ocrelizumab, fingolimod or dimethyl-fumarate administration and in 25 healthy controls (HC). The number of MS patients with viruria increased from 43% at T0 to 100% at T12, whereas it remained similar for the HC group (35-40%). Viremia first occurred 6 months after treatment in MS patients and increased after 12 months, whereas it was absent in HC. The viral load in urine and plasma from the MS cohort increased over time, mostly pronounced in natalizumab-treated patients, whereas it persisted in HC. The archetypal NCCR was detected in all positive urine, whereas mutations were observed in plasma-derived NCCRs resulting in a more neurotropic variant. The prevalence and miR-J1-5p copy number in MS urine and plasma dropped after treatment, whereas they remained similar in HC specimens. Viruria and miR-J1-5p expression did not correlate with anti-JCV index. In conclusion, analyzing JCPyV DNA and miR-J1-5p levels may allow monitoring JCPyV activity and predicting MS patients at risk of developing PML.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Clin Med Año: 2022 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Clin Med Año: 2022 Tipo del documento: Article País de afiliación: Italia